CA
NZ
UK
AU
IND
US
…
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | 26728.10M | 23521.10M | 18470.00M | 12259.10M | 15262.60M |
| Minority interest | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income | 19110.00M | 16563.80M | 12450.00M | 7771.80M | 12518.80M |
| Selling general administrative | 7382.20M | 7722.80M | 6137.60M | 5548.80M | 5794.00M |
| Selling and marketing expenses | 12606.70M | 11296.80M | 10269.90M | 8849.10M | 7426.30M |
| Gross profit | 87401.90M | 80416.30M | 67290.00M | 58813.30M | 56509.30M |
| Reconciled depreciation | 7950.00M | 8080.00M | 7070.00M | 6620.00M | 6580.00M |
| Ebit | 29260.60M | 25723.50M | 21800.00M | 19536.30M | 18673.20M |
| Ebitda | 36758.20M | 33249.00M | 28870.00M | 26155.60M | 25251.10M |
| Depreciation and amortization | 7497.60M | 7525.50M | 7070.00M | 6619.30M | 6577.90M |
| Operating income | 58883.50M | 54979.90M | 21400.20M | 17693.40M | 18227.70M |
| Other operating expenses | 56277.40M | 52298.50M | 73290.00M | 66494.60M | 60578.60M |
| Interest expense | 2520.00M | 3535.60M | 3330.00M | 2529.30M | 3561.60M |
| Tax provision | 7620.00M | 6960.00M | 6020.00M | 4490.00M | 2740.00M |
| Interest income | 2310.70M | 114.80M | 3330.00M | 2550.00M | 3580.00M |
| Net interest income | -2520.00M | -3540.00M | -3330.00M | -2550.00M | -3580.00M |
| Extraordinary items | - | - | - | - | 0.00M |
| Income tax expense | 7615.60M | 6957.30M | 6020.00M | 4487.30M | 2743.80M |
| Total revenue | 115160.90M | 107278.40M | 94640.00M | 84188.00M | 78862.30M |
| Total operating expenses | 28518.40M | 25436.40M | 45940.00M | 41119.90M | 38225.60M |
| Cost of revenue | 27759.00M | 26862.10M | 27350.00M | 25374.70M | 22353.00M |
| Total other income expense net | -32155.40M | -31458.80M | -2928.60M | -5434.30M | -2965.10M |
| Net income from continuing ops | 19110.00M | 16560.00M | 12450.00M | 7770.00M | 12520.00M |
| Net income applicable to common shares | 19112.50M | 16563.80M | 12450.00M | 7771.80M | 12518.80M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 149900.00M | 150605.80M | 150120.00M | 130998.40M | 140746.50M |
| Intangible assets | 42630.00M | 45828.20M | 50890.00M | 35460.60M | 39840.30M |
| Other current assets | 5240.00M | 4841.10M | 3030.00M | 3120.00M | 4510.00M |
| Total liab | 73990.00M | 82044.30M | 88140.00M | 71468.90M | 82374.80M |
| Total stockholder equity | 75910.00M | 68561.50M | 61980.00M | 59529.50M | 58371.70M |
| Other current liab | 10330.00M | 8097.30M | 1030.00M | 990.00M | 1280.00M |
| Common stock | 1690.00M | 1692.30M | 1690.00M | 846.20M | 846.20M |
| Capital stock | 1690.00M | 1690.00M | 1690.00M | 846.20M | 846.20M |
| Retained earnings | 47465.50M | 39424.00M | 33031.90M | 29166.80M | 28064.70M |
| Other liab | - | - | - | 5717.60M | 3825.90M |
| Good will | 3390.00M | 3380.30M | 3380.00M | 2594.80M | 3412.30M |
| Other assets | 6217.30M | 5821.70M | 5436.70M | 6848.00M | 5293.00M |
| Cash | 5790.00M | 8351.40M | 5080.00M | 3984.00M | 5725.60M |
| Cash and equivalents | 2315.20M | 3992.90M | 379.80M | 228.10M | 149.30M |
| Total current liabilities | 47170.00M | 54252.50M | 54470.00M | 44150.90M | 48916.20M |
| Current deferred revenue | - | 45.00M | 8460.00M | 7320.40M | 7859.50M |
| Net debt | 26230.00M | 31868.00M | 48600.00M | 36712.50M | 43015.70M |
| Short term debt | 18640.00M | 23537.00M | 28190.00M | 19096.10M | 19108.60M |
| Short long term debt | 18340.00M | 23340.00M | 28010.00M | 18950.00M | 7040.00M |
| Short long term debt total | 32020.00M | 40219.40M | 53680.00M | 40696.50M | 48741.30M |
| Other stockholder equity | -2504.90M | 714.30M | 27258.10M | 29516.50M | 29460.80M |
| Property plant equipment | 38229.10M | 35777.70M | 34598.40M | 32469.30M | 36287.50M |
| Total current assets | 56230.00M | 56114.80M | 53140.00M | 51649.90M | 55215.00M |
| Net tangible assets | - | - | - | 21474.10M | 15119.10M |
| Short term investments | 1144.90M | 1410.00M | 3270.00M | 1845.50M | 1654.50M |
| Net receivables | 18670.00M | 18443.00M | 19460.00M | 18077.20M | 16512.90M |
| Long term debt | 11920.00M | 16040.00M | 24960.00M | 21230.00M | 29410.00M |
| Inventory | 25410.00M | 22790.70M | 22300.00M | 24623.20M | 26812.00M |
| Accounts payable | 18200.00M | 20893.20M | 16790.00M | 16744.40M | 20668.10M |
| Accumulated other comprehensive income | 26749.10M | 27445.20M | - | - | - |
| Non currrent assets other | 8859.40M | 3233.50M | 1958.90M | 3208.10M | 1093.60M |
| Non current assets total | 93670.00M | 94491.00M | 96980.00M | 79348.50M | 85531.50M |
| Capital lease obligations | 1760.00M | 840.00M | 710.00M | 520.00M | 486.70M |
| Long term debt total | 13376.10M | 16682.40M | 25491.50M | 21600.00M | 29632.70M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -5400.00M | -1680.00M | -24150.00M | -80.90M | -1206.50M |
| Change to liabilities | - | - | - | -4576.70M | 1295.20M |
| Total cashflows from investing activities | -5400.00M | -1679.00M | -24150.00M | -1966.30M | -4494.20M |
| Net borrowings | -9255.00M | -13694.40M | - | -8464.40M | -9562.90M |
| Total cash from financing activities | -22980.00M | -27796.40M | 770.00M | -17810.50M | -16561.30M |
| Net income | 19110.00M | 16563.80M | 18470.00M | 12259.10M | 15262.60M |
| Change in cash | -2621.40M | 3266.10M | 1100.00M | -1741.60M | -892.60M |
| Begin period cash flow | 8351.40M | 5085.30M | 3980.00M | 5725.60M | 6618.20M |
| End period cash flow | 5730.00M | 8351.40M | 5080.00M | 3984.00M | 5725.60M |
| Total cash from operating activities | 25850.00M | 32660.80M | 23680.00M | 18029.90M | 20106.90M |
| Depreciation | 7950.00M | 7953.00M | 7070.00M | 6619.30M | 6577.90M |
| Other cashflows from investing activities | 74.60M | 1467.80M | -18410.00M | 72.40M | 52.50M |
| Dividends paid | 10830.00M | 10153.40M | -8630.00M | -6768.90M | -3384.50M |
| Change to inventory | -2620.00M | -490.00M | 2560.00M | 2188.80M | -5329.80M |
| Change to account receivables | 171.70M | 780.00M | -2897.20M | -1091.10M | 652.10M |
| Other cashflows from financing activities | -2895.00M | -3948.60M | 19120.00M | -711.80M | 1202.20M |
| Change to netincome | - | - | - | 7157.30M | 4397.50M |
| Capital expenditures | 6110.00M | 4327.80M | 5740.00M | 2025.70M | 3351.50M |
| Change in working capital | -4809.30M | 45.30M | -180.00M | -3518.50M | -3382.50M |
| Other non cash items | 3599.30M | 8098.70M | -1680.00M | 2670.00M | 1648.90M |
| Free cash flow | 19740.00M | 28333.00M | 17940.00M | 16004.20M | 16755.40M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(INR) |
Price
(INR) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TORNTPHARM Torrent Pharmaceuticals Limited |
-60.90 1.28% |
4700.10 | 63.48 | 56.50 | 11.13 | 16.39 | 11.65 | 35.91 |
| SUNPHARMA Sun Pharmaceutical Industries Limited |
-12.10 0.64% |
1890.20 | 40.32 | 26.95 | 7.69 | 5.50 | 7.41 | 23.64 |
| DIVISLAB Divi's Laboratories Limited |
83.00 0.73% |
11450.00 | 70.47 | - | 17.47 | 11.44 | 17.33 | 47.08 |
| CIPLA Cipla Limited |
-15.90 1.12% |
1404.00 | 21.74 | 19.01 | 4.23 | 3.76 | 4.08 | 14.00 |
| DRREDDY Dr. Reddy's Laboratories Limited |
11.00 0.80% |
1388.00 | 17.16 | 21.93 | 2.94 | 2.89 | 2.99 | 10.39 |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
| Name | Title | Year Born |
|---|---|---|
| Mr. Samir Uttamlal Mehta | Exec. Chairman & MD | 1964 |
| Mr. Jinesh Shah B.Sc., MBA | Exec. Director of Operations & Whole Time Director | 1977 |
| Mr. Sudhir Menon CA, CWA | Exec. Director of Fin. & CFO | 1972 |
| Mr. Chintan Trivedi | Company Sec. & Compliance Officer | NA |
| Mr. Abdullah Salam Said Al Abri | Chief Customer Service Officer | NA |
| Mr. R. Chandrashekhar Inter CA | VP of Procurement | 1969 |
| Jaydip Bhatt | VP of Human Resource | 1953 |
| H. L. Guttikar B.E., MMS | VP of Projects | 1963 |
| Ashish Hajarnish M.Pharm | VP of Works | 1968 |
| Hasmukh Patel B.Pharm, M.Pharm. | VP of Works | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...